We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+5.61%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$253M
AUM Growth
+$63.7M
(+34%)
Cap. Flow
+$59.7M
Cap. Flow
% of AUM
23.62%
Top 10 Holdings %
Top 10 Hldgs %
44.38%
Holding
92
New
44
Increased
11
Reduced
15
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
|
+$13.9M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$12.1M |
| 3 |
Gilead Sciences
GILD
|
+$10.4M |
| 4 |
Takeda Pharmaceutical
TAK
|
+$8.8M |
| 5 |
Icon
ICLR
|
+$8.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$14.6M |
| 2 |
CELG
Celgene Corp
CELG
|
+$10.8M |
| 3 |
CVS Health
CVS
|
+$8.43M |
| 4 |
SHPG
Shire pic
SHPG
|
+$8.02M |
| 5 |
DaVita
DVA
|
+$7.24M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 74.31% |
| 2 | Technology | 10.37% |
| 3 | Industrials | 2.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Axsome Therapeutics
AXSM
$10.9B
| $744K | 0.29% |
52,268
-156,927
| -75% | -$1.46M |
|
52
Teladoc Health
TDOC
$1.22B
| $731K | 0.29% |
+13,153
| New | +$803K |
|
|
VRAY
53
DELISTED
ViewRay, Inc.
VRAY
| $714K | 0.28% |
+96,580
| New | +$745K |
|
54
PTC Therapeutics
PTCT
$5.77B
| $636K | 0.25% |
+16,903
| New | +$568K |
|
55
Henry Schein
HSIC
$10.2B
| $631K | 0.25% |
+10,503
| New | +$634K |
|
|
56
CVS Health
CVS
$133B
| $595K | 0.24% |
11,036
-136,593
| -93% | -$8.43M |
|
57
Haemonetics
HAE
$3.88B
| $585K | 0.23% |
+6,691
| New | +$608K |
|
|
IMGN
58
DELISTED
Immunogen Inc
IMGN
| $500K | 0.2% |
+184,440
| New | +$799K |
|
59
VistaGen Therapeutics
VTGN
$12.3M
| $462K | 0.18% |
+12,031
| New | +$525K |
|
60
AnaptysBio
ANAB
$1.63B
| $444K | 0.18% |
6,082
-6,652
| -52% | -$459K |
|
61
Surgery Partners
SGRY
$2.05B
| $438K | 0.17% |
+38,805
| New | +$489K |
|
|
ARRY
62
DELISTED
Array Biopharma Inc
ARRY
| $401K | 0.16% |
16,447
-85,898
| -84% | -$1.79M |
|
|
BHVN
63
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $385K | 0.15% |
+7,479
| New | +$323K |
|
|
DVAX
64
DELISTED
Dynavax Technologies
DVAX
| $302K | 0.12% |
+41,288
| New | +$404K |
|
|
GRTS
65
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $283K | 0.11% |
+21,257
| New | +$284K |
|
|
IMGN
66
CALL
DELISTED
Immunogen Inc
IMGN
| $235K | 0.09% |
+86,800
| New | +$376K |
|
67
Aldeyra Therapeutics
ALDX
$93.5M
| $213K | 0.08% |
23,576
-43,063
| -65% | -$366K |
|
|
KA
68
CALL
DELISTED
Kineta, Inc. Common Stock
KA
| $165K | 0.07% |
+933
| New | +$457K |
|
69
Accuray
ARAY
$37.2M
| – | – |
-455,018
| Closed | -$1.55M |
|
70
Axogen
AXGN
$2.47B
| – | – |
-39,961
| Closed | -$816K |
|
71
Boston Scientific
BSX
$71.1B
| – | – |
-30,560
| Closed | -$1.08M |
|
|
72
DaVita
DVA
$14.6B
| – | – |
-140,729
| Closed | -$7.24M |
|
73
Encompass Health
EHC
$11B
| – | – |
-107,187
| Closed | -$5.26M |
|
|
FOLD
74
DELISTED
Amicus Therapeutics
FOLD
| – | – |
-58,240
| Closed | -$558K |
|
|
HOLX
75
DELISTED
Hologic
HOLX
| – | – |
-135,805
| Closed | -$5.58M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2019 Portfolio in Review
As of Q1 2019, Endurant Capital Management held 92 positions worth $253M, up 34% from $189M the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Endurant Capital Management deployed $59.7M of net new capital in Q1 2019, opening 44 new positions and adding to 11 existing holdings. Its largest new stake was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 91% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Allergan plc, an estimated $14.6M trimmed.
- Endurant Capital Management's largest Q1 2019 buy was VOCERA COMMUNICATIONS, INC.: 390,887 shares worth $12.4M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.1M increase.
- Endurant Capital Management's biggest Q1 2019 reduction was Allergan plc, cutting an estimated $14.6M.
- Endurant Capital Management fully exited Celgene Corp in Q1 2019, selling an estimated $10.8M.
- Endurant Capital Management's ten largest holdings make up 44% of its $253M portfolio in Q1 2019.
- Endurant Capital Management opened 44 new positions and closed 22 in Q1 2019.
- Endurant Capital Management's portfolio value rose 34% quarter-over-quarter to $253M.
Based on Endurant Capital Management's 13F filing for Q1 2019, filed 15 May 2019.